<--- Back to Details
First PageDocument Content
Lung cancer / Clinical medicine / Cancer / Tyrosine kinase inhibitors / Boehringer Ingelheim / Health / T790M / Protein kinase inhibitor / Epidermal growth factor receptor / Non-small-cell lung carcinoma / Targeted therapy
Date: 2015-11-24 01:50:17
Lung cancer
Clinical medicine
Cancer
Tyrosine kinase inhibitors
Boehringer Ingelheim
Health
T790M
Protein kinase inhibitor
Epidermal growth factor receptor
Non-small-cell lung carcinoma
Targeted therapy

ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

Add to Reading List

Source URL: www.zailaboratory.com

Download Document from Source Website

File Size: 225,61 KB

Share Document on Facebook

Similar Documents

Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

DocID: 1v2t4 - View Document

Journal of Cellular Biochemistry 103:972–Raf Kinase Inhibitor Protein Positively Regulates Cell–Substratum Adhesion While Negatively Regulating Cell–Cell Adhesion Kevin T. Mc Henry,1 Roberto Montesano,2

Journal of Cellular Biochemistry 103:972–Raf Kinase Inhibitor Protein Positively Regulates Cell–Substratum Adhesion While Negatively Regulating Cell–Cell Adhesion Kevin T. Mc Henry,1 Roberto Montesano,2

DocID: 1uOLU - View Document

Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

DocID: 1r4cq - View Document

ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

DocID: 1qm1i - View Document

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for

DocID: 1pQS7 - View Document